Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Cash & Equivalents (2017 - 2025)

Cue Biopharma (CUE) has disclosed Cash & Equivalents for 9 consecutive years, with $26.6 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 18.44% to $26.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.6 million through Dec 2025, up 18.44% year-over-year, with the annual reading at $26.6 million for FY2025, 18.44% up from the prior year.
  • Cash & Equivalents hit $26.6 million in Q4 2025 for Cue Biopharma, up from $11.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $73.9 million in Q2 2021 to a low of $11.2 million in Q3 2025.
  • Historically, Cash & Equivalents has averaged $45.0 million across 5 years, with a median of $50.1 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: soared 212.64% in 2021 and later plummeted 67.98% in 2025.
  • Year by year, Cash & Equivalents stood at $52.2 million in 2021, then decreased by 1.14% to $51.6 million in 2022, then fell by 6.01% to $48.5 million in 2023, then tumbled by 53.71% to $22.5 million in 2024, then grew by 18.44% to $26.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for CUE at $26.6 million in Q4 2025, $11.2 million in Q3 2025, and $27.5 million in Q2 2025.